Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
04
09
2021
accepted:
20
06
2022
entrez:
22
7
2022
pubmed:
23
7
2022
medline:
23
7
2022
Statut:
epublish
Résumé
Differences in the tumor immune microenvironment may result in differences in prognosis and response to treatment in cancer patients. We hypothesized that differences in the tumor immune microenvironment may exist between African American (AA) and NonAA patients, due to ancestry-related or socioeconomic factors, that may partially explain differences in clinical outcomes. We analyzed clinically matched triple-negative breast cancer (TNBC) tissues from self-identified AA and NonAA patients and found that stromal TILs, PD-L1 IHC-positivity, mRNA expression of immune-related pathways, and immunotherapy response predictive signatures were significantly higher in AA samples (p < 0.05; Fisher's Exact Test, Mann-Whitney Test, Permutation Test). Cancer biology and metabolism pathways, TAM-M2, and Immune Exclusion were significantly higher in NonAA samples (p < 0.05; Permutation Test, Mann-Whitney Test). There were no differences in somatic tumor mutation burden. Overall, there is greater immune infiltration and inflammation in AA TNBC and these differences may impact response to immune checkpoint inhibitors and other therapeutic agents that modulate the immune microenvironment.
Identifiants
pubmed: 35869114
doi: 10.1038/s41523-022-00449-3
pii: 10.1038/s41523-022-00449-3
pmc: PMC9307813
doi:
Types de publication
Journal Article
Langues
eng
Pagination
88Subventions
Organisme : Susan G. Komen (Susan G. Komen Breast Cancer Foundation)
ID : Leadership Award
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Breast Cancer Research Foundation (BCRF)
ID : Award
Organisme : Howard Hughes Medical Institute (HHMI)
ID : Medical Research Fellow Award
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA219647
Informations de copyright
© 2022. The Author(s).
Références
Nat Rev Genet. 2021 May;22(5):284-306
pubmed: 33432191
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Clin Cancer Res. 2020 Apr 15;26(8):1977-1984
pubmed: 31919134
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Breast Cancer Res Treat. 2015 May;151(1):99-111
pubmed: 25868865
Breast Cancer Res Treat. 2019 May;175(1):247-259
pubmed: 30725384
Methods Mol Biol. 2020;2117:135-157
pubmed: 31960376
Sci Rep. 2020 Sep 25;10(1):15750
pubmed: 32978482
Clin Cancer Res. 2008 Aug 1;14(15):4780-6
pubmed: 18676748
Asian Pac J Cancer Prev. 2019 Nov 01;20(11):3465-3472
pubmed: 31759373
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Gene X. 2019 Nov 06;5:100023
pubmed: 32550552
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Mod Pathol. 2020 Sep;33(9):1746-1752
pubmed: 32300181
Immunity. 2021 Feb 9;54(2):367-386.e8
pubmed: 33567262
Breast Cancer Res Treat. 2007 May;102(3):347-56
pubmed: 17028980
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
J Immunol Res. 2016;2016:4326495
pubmed: 27652273
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
J Clin Oncol. 2015 Dec 20;33(36):4267-76
pubmed: 26598753
Clin Cancer Res. 2004 Apr 15;10(8):2797-803
pubmed: 15102687
Curr Cancer Drug Targets. 2015;15(8):652-64
pubmed: 26452382
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
J Natl Cancer Inst. 2021 Feb 1;113(2):146-153
pubmed: 33152071
Cell Death Dis. 2020 Oct 30;11(10):933
pubmed: 33127882
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Anticancer Res. 2019 Nov;39(11):6125-6133
pubmed: 31704840
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
Breast Cancer Res Treat. 2009 Jan;113(2):357-70
pubmed: 18324472
Cancer. 2006 Dec 1;107(11):2662-8
pubmed: 17061247
Lancet. 2020 Oct 10;396(10257):1090-1100
pubmed: 32966830
Nat Med. 2018 Oct;24(10):1550-1558
pubmed: 30127393
Cancer Immunol Res. 2015 Apr;3(4):326-32
pubmed: 25527356
Anticancer Res. 2015 Dec;35(12):6551-61
pubmed: 26637869
J Clin Oncol. 2010 Oct 1;28(28):4316-23
pubmed: 20805453
Oncogene. 2007 Sep 13;26(42):6113-24
pubmed: 17452986
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Cancers (Basel). 2020 Oct 18;12(10):
pubmed: 33081025
BMC Bioinformatics. 2011 Aug 04;12:323
pubmed: 21816040
Genome Med. 2020 Feb 26;12(1):21
pubmed: 32102694
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Bioinformatics. 2008 Mar 1;24(5):719-20
pubmed: 18024473
Lancet Oncol. 2021 Apr;22(4):499-511
pubmed: 33676601
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Front Immunol. 2020 Aug 14;11:1685
pubmed: 32922387
J Clin Pathol. 2020 Aug;73(8):456-462
pubmed: 31796638
J Natl Cancer Inst. 2009 Jul 15;101(14):984-92
pubmed: 19584328
Ann Oncol. 2019 Dec 1;30(12):1941-1949
pubmed: 31566659
J Natl Cancer Inst. 2021 Aug 2;113(8):1036-1043
pubmed: 33395700
Nat Commun. 2013;4:2612
pubmed: 24113773
Expert Opin Biol Ther. 2020 Feb;20(2):105-108
pubmed: 31755317
Cancer Med. 2016 Aug;5(8):2000-11
pubmed: 27184932